The EPS projection of Bristol-Myers Squibb Company (NYSE:BMY) for quarter ended 2016-09-30 is $0.64. Last week, the EPS forecast was $0.64 against target of $0.64, a month earlier. Two months ago, this estimate was $0.64 versus forecast of $0.64 three months earlier, implying a deviation of 0%.
Bristol-Myers Squibb Company (NYSE:BMY) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 5, 4, and 5, correspondingly.
EPS estimate downgrade for Bristol-Myers Squibb Company (NYSE:BMY) in the preceding 30, 120, 60 and 90 days were 0, 0, 0, and 0, correspondingly.
Bristol-Myers Squibb Company (NYSE:BMY) EPS target for the quarter closed 1 was $0.64, based on 10 recommendations. As reported on 2016-04-28 the EPS was $0.74. The change was $0.08, implying a percentage deviation of 12.12%. The projections showed a standard deviation of 0.03.
Quarterly Sales Estimates
Bristol-Myers Squibb Company (NYSE:BMY) yearly sales prediction for the fiscal 2016 stands at $4865.7 and the median estimate is at $4840.1. Almost 3 analysts issued sales target.
Highest sales target is $4962 while the lowest target is $4795 showing standard deviation of 86.393%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 1.946%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. Bristol-Myers Squibb Company (NYSE:BMY) announced that the deviation in forecast was 4.235%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...